Literature DB >> 27071045

Diagnostics of Inherited Bleeding Disorders of Secondary Hemostasis: An Easy Guide for Routine Clinical Laboratories.

Giuseppe Lippi1, Massimo Franchini2, Emmanuel J Favaloro3.   

Abstract

The investigation of inherited bleeding disorders of secondary hemostasis remains a challenge for most clinical laboratories, especially those that lack experience or specialized personnel. Bleeding can be essentially caused by a variety of acquired or congenital conditions, which impair either primary or secondary hemostasis. Since a universally agreed approach for the diagnostics of hemorrhagic disorders is still unavailable, this article aims to provide an easy guidance for routine clinical laboratories. This pragmatic approach to identifying and diagnosing inherited bleeding disorders of secondary hemostasis entails a multifaceted strategy, based on a collection of personal and family history, the results of first-line tests, which can then be followed by second- or third-line analyses to definitely establish the specific nature and the severity of the bleeding phenotype. Briefly, the presence of profound hemorrhages rather than mucocutaneous bleeding is suggestive of a disorder of secondary hemostasis. Although a positive family history is frequently reported in patients with congenital conditions, the lack of clinically meaningful symptoms in patient's relatives is not absolutely indicative of an acquired disorder. The next step encompasses the assessment of first-line coagulation tests (i.e., prothrombin time, activated partial thromboplastin time, and fibrinogen) if family history is not suggestive of a specific factor deficiency. The emergence of abnormal data of these assays and the variable combination of their results is then helpful to guide the performance of second-line tests, in particular specific factor assays, which will then provide a reasonable basis for a preliminary diagnosis. Third-line tests (namely, immunological assays of clotting factors and molecular biology) are then supportive for a final diagnosis and for identifying the nature of the factor deficiency (i.e., quantitative or functional). Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2016        PMID: 27071045     DOI: 10.1055/s-0036-1571311

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  6 in total

1.  What should be the laboratory approach against isolated prolongation of a activated partial thromboplastin time?

Authors:  Mesude Falay; Mehmet Senes; Dogan Yücel; Turan Turhan; Simten Dagdaş; Melike Pekin; Namik K Nazaroglu; Gülsüm Özet
Journal:  J Clin Lab Anal       Date:  2018-02-27       Impact factor: 2.352

2.  Combined use of Clauss and prothrombin time-derived methods for determining fibrinogen concentrations: Screening for congenital dysfibrinogenemia.

Authors:  Liqun Xiang; Meiling Luo; Jie Yan; Lin Liao; Weijie Zhou; Xuelian Deng; Donghong Deng; Peng Cheng; Faquan Lin
Journal:  J Clin Lab Anal       Date:  2017-09-18       Impact factor: 2.352

3.  Cryptogenic oozers and bruisers.

Authors:  Kristi J Smock; Karen A Moser
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

4.  Impact of experimental hypercalcemia on routine haemostasis testing.

Authors:  Giuseppe Lippi; Gian Luca Salvagno; Giorgio Brocco; Matteo Gelati; Elisa Danese; Emmanuel J Favaloro
Journal:  PLoS One       Date:  2017-03-31       Impact factor: 3.240

5.  Hypofibrinogenaemia: A Case of Spontaneous Bleeding and Central Venous Thrombosis in the Same Lifetime.

Authors:  Adriana Watts Soares; Maria Maia; João Espirito Santo; Ana Palricas Costa; Artur Pereira; Cristina Catarino
Journal:  Eur J Case Rep Intern Med       Date:  2020-01-28

6.  [Consensus of Chinese expert on the diagnosis and treatment of rare bleeding disorders (version 2021)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-02-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.